Achim Rittmeyer

机构：Imerys (Germany) · ORCID：0000-0002-5280-6052

发表论文 171 篇 · 总被引 15262 次 · h-index 36

代表论文

• Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial (2025 · Journal of Clinical Oncology · 被引 44)
• Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort (2026 · Journal of Thoracic Oncology · 被引 3)
• PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) (2025 · Annals of Oncology · 被引 3)
• Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study (2025 · Journal of Thoracic Oncology · 被引 3)
• Abstract CT215: RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC (2026 · Cancer Research · 被引 2)
• MA08.03 First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2 (2025 · Journal of Thoracic Oncology · 被引 2)